- Ombudsman and campaigners attack "dilution" of EMA data disclosure policy
- EMA rejects claims of undue industry influence on data disclosure policy
- EU reveals proposals on pharma in TTIP talks
- US Capitol Capsule: Rare disease sector matures; FDA keeping pace?
- The EMA at 20: Guido Rasi looks at how the EU regulatory landscape might change over the next decade
- PROFILE: Vas Narasimhan on many Novartis roles, extinction fears and Hilleman influences